|
KaloBios calls it quits on its asthma drug after a Phase II flop
FierceBiotech San Francisco's KaloBios ($KBIO) is hitting the breaks on one of its lead programs after the asthma treatment missed its primary endpoint in a mid-stage trial, sending the company's shares into a 30% tailspin. The drug, KB003, failed to significantly … KaloBios Pharma pulls plug on asthma drug, shares plunge KaloBios stock slides; to stop asthma study KaloBios: KB003 Fails To Meet Primary Goal In Phase 2 Asthma Study |
View full post on asthma – Google News